Replies to post #17955 on Health Discovery Corp (HDVY)

[Zenos Arrow]

>>> strike gold here and I'll strangle that leprechaun>>>

I swear I’m going to collect these Loc’isms over the years and submit them in one final post.

I don’t think the number of AI patents is as pertinent as the patents themselves.

As far as the number: I believe the proliferation of AI patents equals “acceptance” within these industries – so that could only be a good indicator, if we actualized Fromholzer’s statement.

As far as the patents themselves: Ours have done well in the clinical diagnostics sector.
Ciphergen/Vermillion/Aspira Labs’ Ova1 (proteomic test) was developed in conjunction with Quest Diagnostics; seemingly minutes after we collected our settlement. Neogenomics’ profited off our patent in its flow cytometry (analyzing large data sets for cancer testing). I often wonder who else in this big-date driven sub-sector of biotechnology.

I can make a case for HDC still commercializing their technology when the patents expire (I offered Myriad’s BRCA genes patent as an example).

We would need a proper, commensurate settlement, along with a company commitment to commercialize our patents. But again, my argument is mostly around the “more to come” regarding our settlement (whatever that might be).